ArticleAnnals of medicine and surgery (2012)2026
A network meta-analysis of safety and efficacy of sodium-glucose cotransporter 2 inhibitors in heart failure patients.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have shown promise in treating heart failure (HF), but the best choice among these drugs remains unclear. This study aims to compare the effectiveness and safety of different SGLT2is in HF patients. Methods: We conducted a comprehensive search of 5 databases (PubMed, Scopus, Web of Science, Embase, and ClinicalTrials.gov) for randomized controlled trials (RCTs) conducted up until March 2023. These trials had to compare SGLT2i medications to a placebo in patients with HF. The main outcomes were all-cause mortality, cardiovascular mortality, hospitalization due to HF, and myocardial infarction (MI). Furthermore, we calculated the risk ratio (RR) with a 95% confidence interval (CI) using the random-effects model and inverse variance statistics. Results: We included 16 RCTs involving 80 666 patients (43 743 on SGLT2 inhibitors, 36 923 on placebo). No SGLT2 inhibitor demonstrated a significant difference in all-cause mortality and MI compared to others. However, empagliflozin significantly reduced the risk of cardiovascular mortality by 20% (RR: 0.80, 95% CI 0.69-0.93), including in patients with diabetes. All SGLT2 inhibitors lowered the risk of hospitalization for HF compared to placebo, except for canagliflozin. Sotagliflozin had the greatest reduction in hospitalizations (RR: 0.66, 95% CI 0.57-0.76), followed by empagliflozin (RR 0.73, 95% CI 0.66-0.81). There were no significant differences among SGLT2 inhibitors for stroke or drug discontinuation due to side effects. Notably, empagliflozin had a 13% lower risk of serious adverse events (RR 0.87, 95% CI 0.76-0.99). Conclusion: Empagliflozin was associated with the lowest risk of both cardiovascular mortality and serious side effects. While all SGLT2 inhibitors reduced the likelihood of hospitalizations for HF, canagliflozin did not show a significant benefit in this area. There were no significant differences between the SGLT2 inhibitors in terms of all-cause mortality, MI, stroke, or side effects leading to treatment discontinuation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.